MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy

Current Diabetes Reports

Volumn 16, Issue 3, 2016, Pages

  Simpson, Kate ^a   Wonnacott, Alexa ^a   Fraser, Donald J ^a   Bowen, Timothy ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Biomarker; Diabetic nephropathy; Fibrosis; MicroRNA; Non coding RNA; Therapeutics

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING MICRORNA; DOUBLE STRANDED RNA; MESSENGER RNA; MICRORNA; MICRORNA 122; MICRORNA 141; MICRORNA 155; MICRORNA 16; MICRORNA 192; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 210; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; MICRORNA 34A; MICRORNA 429; MICRORNA 744; MICRORNA 93; MICRORNA LET 7; MICRORNA LIN 4; SINGLE STRANDED RNA; UNCLASSIFIED DRUG; GENETIC MARKER;

3' UNTRANSLATED REGION; BIOGENESIS; CELL COMMUNICATION; DIABETIC NEPHROPATHY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REPRESSION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; KIDNEY FIBROSIS; MOLECULAR CLONING; NONHUMAN; PATHOGENESIS; PROTEINURIA; REVIEW; RNA ANALYSIS; RNA STABILITY; RNA TRANSLATION; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; URINE LEVEL; ANIMAL; ANTIBODY SPECIFICITY; CHRONIC KIDNEY FAILURE; DISEASE COURSE; GENETIC MARKER; GENETICS;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GENETIC MARKERS; HUMANS; MICRORNAS; ORGAN SPECIFICITY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84960956976     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-016-0724-8     Document Type: Review

References (58)

1. World Health Organisation. Global status on noncommunicable diseases. Geneva: World Health Organisation; 2014.
2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72. doi:10.1016/S0140-6736(13)60687-X.
3. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med. 1989;321(16):1074–9. doi:10.1056/NEJM198910193211603.
4. Regele F, Jelencsics K, Shiffman D, Pare G, McQueen MJ, Mann JF, et al. Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. Nephrol Dial Transplant. 2015;30 Suppl 4:iv26–34. doi:10.1093/ndt/gfv087.
5. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325(12):836–42. doi:10.1056/NEJM199109193251202.
6. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004;25(6):971–1010. doi:10.1210/er.2003-0018.
7. Coward RJ, Saleem MA. Podocytes as a target of insulin. Curr Diabetes Rev. 2011;7(1):22–7.
8. Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012;60(12):976–86. doi:10.1369/0022155412465073.
9. Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Tubulointerstitial damage and progression of renal failure. Kidney Int Suppl. 2005;99:S82–6. doi:10.1111/j.1523-1755.2005.09915.x.
10. Lee RC, Feinbaum RL, Ambros C. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.
11. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901–6. doi:10.1038/35002607.
12. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86–9. doi:10.1038/35040556.
13. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001;294(5543):862–4. doi:10.1126/science.1065329.
14. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 2006;125(5):887–901. doi:10.1016/j.cell.2006.03.043.
15. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18(24):3016–27. doi:10.1101/gad.1262504.
16. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304(5670):594–6. doi:10.1126/science.1097434.
17. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–9. doi:10.1073/pnas.242606799.
18. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793–801. doi:10.1056/NEJMoa050995.
19. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735–9.
20. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401–14. doi:10.1016/j.cell.2007.04.040.
21. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9. doi:10.1038/ncb1596.
22. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8. doi:10.1073/pnas.0804549105.
23. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672–5. doi:10.1111/j.1365-2141.2008.07077.x.
24. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897–912. doi:10.3892/ijo.2012.1647.
25. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003–8. doi:10.1073/pnas.1019055108. This study provides data on factors stabilizing circulating miRNAs, and identifies discrete EVA- and NVA-miRNA populations.
26. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–33. doi:10.1093/nar/gkr254.
27. Beltrami C, Clayton A, Phillips AO, Fraser DJ, Bowen T. Analysis of urinary microRNAs in chronic kidney disease. Biochem Soc Trans. 2012;40(4):875–9. doi:10.1042/BST20120090.
28. Lotvall J, Valadi H. Cell to cell signalling via exosomes through esRNA. Cell Adh Migr. 2007;1(3):156–8.
29. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38(20):7248–59. doi:10.1093/nar/gkq601.
30. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–33. doi:10.1038/ncb2210.
31. Sharkey JW, Antoine DJ, Park BK. Validation of the isolation and quantification of kidney enriched miRNAs for use as biomarkers. Biomarkers. 2012;17(3):231–9. doi:10.3109/1354750X.2012.657246.
32. Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am J Nephrol. 2012;36(5):412–8. doi:10.1159/000343452.
33. Beltrami C, Clayton A, Newbury LJ, Corish C, Jenkins RH, Phillips AO, et al. Stabilization of urinary microRNAs by association with exosomes and argonaute 2 protein. Non-Coding RNA. 2015;1(2):151–65. doi:10.3390/ncrna1020151.
34. Argyropoulos C, Wang K, McClarty S, Huang D, Bernardo J, Ellis D, et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One. 2013;8(1), e54662. doi:10.1371/journal.pone.0054662.
35. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012;7(3), e30679. doi:10.1371/journal.pone.0030679.
36. Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A. 2014;111(41):14888–93. doi:10.1073/pnas.1408301111.
37. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454(7200):56–61. doi:10.1038/nature07086.
38. Martin J, Jenkins RH, Bennagi R, Krupa A, Phillips AO, Bowen T, et al. Post-transcriptional regulation of transforming growth factor beta-1 by microRNA-744. PLoS One. 2011;6(10), e25044. doi:10.1371/journal.pone.0025044.
39. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104(9):3432–7. doi:10.1073/pnas.0611192104.
40. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):438–47. doi:10.1681/ASN.2009050530.
41. Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes. 2010;59(7):1794–802. doi:10.2337/db09-1736.
42. Jenkins RH, Martin J, Phillips AO, Bowen T, Fraser DJ. Pleiotropy of microRNA-192 in the kidney. Biochem Soc Trans. 2012;40(4):762–7. doi:10.1042/BST20120085.
43. Zhong X, Chung AC, Chen HY, Dong Y, Meng XM, Li R, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia. 2013;56(3):663–74. doi:10.1007/s00125-012-2804-x. This study describes overexpression and downregulation of miR-21 in disease models, and subsequent findings showing profibrotic and antifibrotic effects, respectively.
44. Lin L, Gan H, Zhang H, Tang W, Sun Y, Tang X, et al. MicroRNA21 inhibits SMAD7 expression through a target sequence in the 3′ untranslated region and inhibits proliferation of renal tubular epithelial cells. Mol Med Rep. 2014;10(2):707–12. doi:10.3892/mmr.2014.2312.
45. Bracken CP, Khew-Goodall Y, Goodall GJ. Network-based approaches to understand the roles of miR-200 and other microRNAs in cancer. Cancer Res. 2015;75(13):2594–9. doi:10.1158/0008-5472.CAN-15-0287.
46. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22(7):894–907. doi:10.1101/gad.1640608.
47. Kato M, Arce L, Wang M, Putta S, Lanting L, Natarajan R. A microRNA circuit mediates transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells. Kidney Int. 2011;80(4):358–68. doi:10.1038/ki.2011.43.
48. Lin CL, Lee PH, Hsu YC, Lei CC, Ko JY, Chuang PC, et al. MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. J Am Soc Nephrol. 2014;25(8):1698–709. doi:10.1681/ASN.2013050527.
49. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8), e6816. doi:10.1371/journal.pone.0006816.
50. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70(14):5923–30. doi:10.1158/0008-5472.CAN-10-0655.
51. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198–201. doi:10.1126/science.1178178.
52. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012;23(3):458–69. doi:10.1681/ASN.2011050485.
53. Kato M, Natarajan R. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Ann N Y Acad Sci. 2015. doi:10.1111/nyas.12758.
54. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem. 2011;286(13):11837–48. doi:10.1074/jbc.M110.194969.
55. Sun L, Zhang D, Liu F, Xiang X, Ling G, Xiao L, et al. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol. 2011;225(3):364–77. doi:10.1002/path.2961.
56. Deelman LE, Declèves AE, Rychak JJ, Sharma K. Targeted renal therapies through microbubbles and ultrasound. Adv Drug Deliv Rev. 2010;62(14):1369–77. doi:10.1016/j.addr.2010.10.002.
57. Sirsi S, Borden M. Microbubble compositions, properties and biomedical applications. Bubble Sci Eng Technol. 2009;1(1-2):3–17. doi:10.1179/175889709X446507.
58. Bowen T, Jenkins RH, Fraser DJ. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J Pathol. 2013;229(2):274–85. doi:10.1002/path.4119.